View Financial HealthThis company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsSilver Phoenix Resources 配当と自社株買い配当金 基準チェック /06主要情報n/a配当利回り0%バイバック利回り総株主利回り0%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Jun 18Silver Phoenix Resources Inc., Annual General Meeting, Jul 28, 2022Silver Phoenix Resources Inc., Annual General Meeting, Jul 28, 2022.お知らせ • Apr 13Atlas Biotechnologies Inc. & AgMedica Bioscience Inc. & Cambrosia Ltd. entered into a binding memorandum of understanding to acquire Silver Phoenix Resources Inc. (CNSX:SP) for approximately CAD 190 million in a reverse merger transaction.Atlas Biotechnologies Inc. & AgMedica Bioscience Inc. & Cambrosia Ltd. entered into a binding memorandum of understanding to acquire Silver Phoenix Resources Inc. (CNSX:SP) (SPR) for approximately CAD 190 million in a reverse merger transaction on April 8, 2022. As a part of transaction, the shareholders of Atlas Biotechnologies Inc. & AgMedica Bioscience Inc. & Cambrosia Ltd. will be issued common shares of Silver Phoenix Resources Inc. with an aggregate deemed value of CAD 189 million. The MOU also provides that effective on closing of the Proposed Transaction SPR will, among other things: (i) change its name to a name requested by Atlas Biotechnologies Inc. & AgMedica Bioscience Inc. & Cambrosia Ltd. and acceptable to applicable regulatory authorities; (ii) increase the size of its board of directors to between five and nine and (ii) replace all directors and officers of the Company on closing of the Proposed Transaction with nominees of Atlas Biotechnologies Inc. & AgMedica Bioscience Inc. & Cambrosia Ltd. On completion of the Proposed Transaction, SPR's Board of Directors and management team will be reconstituted to include Sheldon Croome, Chief Executive Officer; Jeffrey R. Gossain, President and Kevin Mills, Chief Financial Officer. Completion of the Proposed Transaction is subject to a number of conditions, including receipt of all necessary shareholder and regulatory approvals, execution of related transaction documents, approval of the Exchange, disposition of SPR's mining assets, there being no adverse material change in the affairs of the parties and completion of satisfactory due diligence by each of the parties. The MOU shall terminate upon any party notifying the others that it is not satisfied with the results of its due diligence investigation by April 30, 2022. Closing of the Proposed Transaction will take place in the second or third quarter of 2022 and in any event prior to October 31, 2022. Kronos Capital Partners acted as financial advisor to Agmedica Bioscience Inc. with respect to the Proposed Transaction.Board Change • Mar 05Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. President, CEO, Corporate Secretary & Director Scott Ackerman was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Feb 11Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. President, CEO, Corporate Secretary & Director Scott Ackerman was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. President, CEO, Corporate Secretary & Director Scott Ackerman was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.決済の安定と成長配当データの取得安定した配当: SPの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: SPの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Silver Phoenix Resources 配当利回り対市場SP 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (SP)n/a市場下位25% (CA)1.7%市場トップ25% (CA)5.5%業界平均 (Metals and Mining)1.4%アナリスト予想 (SP) (最長3年)n/a注目すべき配当: SPは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: SPは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: SPの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: SPが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YCA 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2022/06/27 02:37終値2022/03/30 00:00収益2022/03/31年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Silver Phoenix Resources Inc. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jun 18Silver Phoenix Resources Inc., Annual General Meeting, Jul 28, 2022Silver Phoenix Resources Inc., Annual General Meeting, Jul 28, 2022.
お知らせ • Apr 13Atlas Biotechnologies Inc. & AgMedica Bioscience Inc. & Cambrosia Ltd. entered into a binding memorandum of understanding to acquire Silver Phoenix Resources Inc. (CNSX:SP) for approximately CAD 190 million in a reverse merger transaction.Atlas Biotechnologies Inc. & AgMedica Bioscience Inc. & Cambrosia Ltd. entered into a binding memorandum of understanding to acquire Silver Phoenix Resources Inc. (CNSX:SP) (SPR) for approximately CAD 190 million in a reverse merger transaction on April 8, 2022. As a part of transaction, the shareholders of Atlas Biotechnologies Inc. & AgMedica Bioscience Inc. & Cambrosia Ltd. will be issued common shares of Silver Phoenix Resources Inc. with an aggregate deemed value of CAD 189 million. The MOU also provides that effective on closing of the Proposed Transaction SPR will, among other things: (i) change its name to a name requested by Atlas Biotechnologies Inc. & AgMedica Bioscience Inc. & Cambrosia Ltd. and acceptable to applicable regulatory authorities; (ii) increase the size of its board of directors to between five and nine and (ii) replace all directors and officers of the Company on closing of the Proposed Transaction with nominees of Atlas Biotechnologies Inc. & AgMedica Bioscience Inc. & Cambrosia Ltd. On completion of the Proposed Transaction, SPR's Board of Directors and management team will be reconstituted to include Sheldon Croome, Chief Executive Officer; Jeffrey R. Gossain, President and Kevin Mills, Chief Financial Officer. Completion of the Proposed Transaction is subject to a number of conditions, including receipt of all necessary shareholder and regulatory approvals, execution of related transaction documents, approval of the Exchange, disposition of SPR's mining assets, there being no adverse material change in the affairs of the parties and completion of satisfactory due diligence by each of the parties. The MOU shall terminate upon any party notifying the others that it is not satisfied with the results of its due diligence investigation by April 30, 2022. Closing of the Proposed Transaction will take place in the second or third quarter of 2022 and in any event prior to October 31, 2022. Kronos Capital Partners acted as financial advisor to Agmedica Bioscience Inc. with respect to the Proposed Transaction.
Board Change • Mar 05Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. President, CEO, Corporate Secretary & Director Scott Ackerman was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Feb 11Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. President, CEO, Corporate Secretary & Director Scott Ackerman was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. President, CEO, Corporate Secretary & Director Scott Ackerman was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.